Senores Pharmaceuticals Limited — Updates, 15-05-2025: Press Release

Senores Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. FY25 revenue jumped 91% to Rs. 410 Cr, EBITDA climbed 145% to Rs. 102 Cr, and PBT rose 183% to Rs. 71 Cr. Regulated market revenue increased 69% to Rs. 245 Cr, backed by a growing ANDA portfolio and CDMO/CMO segment gains. Emerging markets revenue surged 174% to Rs. 121 Cr with better margins. Recent acquisitions added 15 ANDAs, boosting government contract potential. Focus remains on ANDA expansion, scaling CDMO/CMO, and improving emerging market profitability.